Skip to main content

Advertisement

ADVERTISEMENT

AP Insights, News, Videos, and More

News
06/12/2023
Tom Valentino, Digital Managing Editor
Leaders from the National Institutes of Health and the US Food and Drug Administration have highlighted the need to address gaps in research, development, and implementation of rapid drug-detecting tools to prevent overdose deaths.
Leaders from the National Institutes of Health and the US Food and Drug Administration have highlighted the need to address gaps in research, development, and implementation of rapid drug-detecting tools to prevent overdose deaths.
Leaders from the National...
06/12/2023
Addiction Professional
News
06/09/2023
Tom Valentino, Digital Managing Editor
Past-year use of non-LSD hallucinogens among young adults between the ages of 19 and 30 nearly doubled, according to a study conducted by researchers from the University of Michigan and Columbia University.
Past-year use of non-LSD hallucinogens among young adults between the ages of 19 and 30 nearly doubled, according to a study conducted by researchers from the University of Michigan and Columbia University.
Past-year use of non-LSD...
06/09/2023
Addiction Professional
Drew Dutton, MEd, MBA, LPC-S, LCDC, ACPS
News
06/05/2023
Tom Valentino, Digital Managing Editor
Drew Dutton, MEd, MBA, LPC-S, LCDC, ACPS, the president and CEO of Phoenix House Texas, who presented at the West Coast Symposium on Saturday, explains why addiction treatment modalities that work for adults may not have the same efficacy...
Drew Dutton, MEd, MBA, LPC-S, LCDC, ACPS, the president and CEO of Phoenix House Texas, who presented at the West Coast Symposium on Saturday, explains why addiction treatment modalities that work for adults may not have the same efficacy...
Drew Dutton, MEd, MBA, LPC-S,...
06/05/2023
Addiction Professional
John de Miranda, EdM, CRC
News
06/02/2023
Tom Valentino, Digital Managing Editor
West Coast Symposium presenter John de Miranda, EdM, CRC, explains why 2022 was a breakout year for the integration of harm reduction practices within the addiction treatment field, but significant work remains.
West Coast Symposium presenter John de Miranda, EdM, CRC, explains why 2022 was a breakout year for the integration of harm reduction practices within the addiction treatment field, but significant work remains.
West Coast Symposium presenter...
06/02/2023
Addiction Professional
Aaron Olson
News
06/01/2023
Tom Valentino, Digital Managing Editor
West Coast Symposium presenter Aaron Olson, MS, CMHC, SUDC, discusses the signs and symptoms of compassion fatigue, burnout, and trauma, and offers interventions to help practitioners restore their compassion resilience.
West Coast Symposium presenter Aaron Olson, MS, CMHC, SUDC, discusses the signs and symptoms of compassion fatigue, burnout, and trauma, and offers interventions to help practitioners restore their compassion resilience.
West Coast Symposium presenter...
06/01/2023
Addiction Professional
News
05/24/2023
Tom Valentino, Digital Managing Editor
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new...
05/24/2023
Addiction Professional
News
05/23/2023
Tom Valentino, Digital Managing Editor
The US Food and Drug Administration has approved Opvee, a new opioid overdose reversal nasal spray for patients at least 12 years of age. The medication was developed by a pharmaceutical company within the Indivior portfolio.
The US Food and Drug Administration has approved Opvee, a new opioid overdose reversal nasal spray for patients at least 12 years of age. The medication was developed by a pharmaceutical company within the Indivior portfolio.
The US Food and Drug...
05/23/2023
Addiction Professional
Lawrence Weinstein, MD
Perspectives
05/23/2023
Lawrence Weinstein, MD
Despite being classified as an emerging drug threat by the Office of National Drug Control Policy, xylazine is still flying under the radar for many providers. Here is the least you need to know about the drug also known as "tranq."
Despite being classified as an emerging drug threat by the Office of National Drug Control Policy, xylazine is still flying under the radar for many providers. Here is the least you need to know about the drug also known as "tranq."
Despite being classified as an...
05/23/2023
Addiction Professional
News
05/16/2023
Tom Valentino, Digital Managing Editor
A study by researchers at Harvard University and Dartmouth College shows a discrepancy in the rates in which various populations receive medications for opioid use disorder despite making a similar number of visits to healthcare providers.
A study by researchers at Harvard University and Dartmouth College shows a discrepancy in the rates in which various populations receive medications for opioid use disorder despite making a similar number of visits to healthcare providers.
A study by researchers at...
05/16/2023
Addiction Professional
News
05/12/2023
Tom Valentino, Digital Managing Editor
NYU Langone Health and Brown University’s School of Public Health have received a $5 million grant to study the individual- and community-level impact of overdose prevention centers in New York and Rhode Island.
NYU Langone Health and Brown University’s School of Public Health have received a $5 million grant to study the individual- and community-level impact of overdose prevention centers in New York and Rhode Island.
NYU Langone Health and Brown...
05/12/2023
Addiction Professional

Advertisement

Advertisement